22C Target Pharma Investors Rollover, LLC is a private investment fund based in New York, New York. According to its most recent Form D, filed Jul 23, 2018, it has sold $18,250,000 of interests to 4 investors since its first sale in Jun 2018. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Eric Edell; D. Winn.
- Total raised
- $18,250,000Cumulative sales reported on Form D
- Investors
- 4
- First sale
- Jun 28, 2018
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Eric Edell; D. Winn
- Latest Form D
- Jul 23, 2018
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about 22C Target Pharma Investors Rollover, LLC
What is the minimum investment for 22C Target Pharma Investors Rollover, LLC?
22C Target Pharma Investors Rollover, LLC's latest Form D, filed Jul 23, 2018, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in 22C Target Pharma Investors Rollover, LLC?
22C Target Pharma Investors Rollover, LLC is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has 22C Target Pharma Investors Rollover, LLC raised?
22C Target Pharma Investors Rollover, LLC reports $18,250,000 sold from 4 investors on its Form D filed Jul 23, 2018. This is cumulative sales since the offering began, not current assets or performance.
Where is 22C Target Pharma Investors Rollover, LLC based?
22C Target Pharma Investors Rollover, LLC is based in New York, New York.
When did 22C Target Pharma Investors Rollover, LLC launch?
22C Target Pharma Investors Rollover, LLC reports its first sale in Jun 2018.
Size compared with every private investment fund
Raised more than 54% of the 2,862 private investment funds based in New York, and more than 50% of all 10,377 that report sales.